相关实验视频
Updated: Mar 17, 2026

11:45
Quantifying Agonist Activity at G Protein-coupled Receptors
Published on: December 26, 2011
19.9K
动态药解剂揭示了M2受体上的经典部分激动剂的绑定模式组合
Friederike Wunsch1, Michael Kauk2, Jenny Filor2
1Institute for Pharmaceutical and Medicinal Chemistry, University of Münster, 48149 Münster, Germany.
Journal of chemical information and modeling
|March 16, 2026
概括
对于M2受体,奥托斯特的部分激动剂可以稳定不同的受体状态. 动态的药模型揭示了联结体相互作用如何影响疗效,有助于设计更安全,更有效的药物.
科学领域:
- 药理学 药理学是指药理学的学科.
- 结构生物学 结构生物学
- 计算化学的计算化学
背景情况:
- 众所周知,M2受体的双星部分激动剂可以稳定活性和非活性状态.
- ортостерик局部激动剂与M2受体相互作用的机制在很大程度上仍然未被描述.
研究的目的:
- 研究经典M2部分激动剂的结合模式.
- 探索连接体结合和受体疗效之间的关系.
主要方法:
- 应用动态药模型的应用.
- 绑定模式组合的分析.
- 脂友性接触分布与连接剂疗效的相关性.
主要成果:
- 揭露了M2部分激动剂的结合模式组合.
- 鉴定了脂友性接触者与连接剂疗效之间的相关性.
- 证明了动态药模型用于分析微妙的结合模式改变的实用性.
结论:
- орто斯特的部分激动剂可能会表现出复杂的结合机制,影响M2受体状态.
- 了解这些机制对于开发具有提高疗效和减少副作用的向疗法至关重要.
- 动态药模拟为M2受体调节器的基于结构的药物设计提供了一种有价值的方法.
更多相关视频
相关概念视频
Cholinergic Receptors: Muscarinic
5.8K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine.
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
5.8K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
2.4K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
2.4K
Direct-Acting Cholinergic Agonists: Pharmacological Actions
2.5K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.5K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
3.0K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
3.0K
Drug-Receptor Interaction: Agonist
4.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.5K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
1.1K
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
1.1K

